Supplemental Oxygen in Pulmonary Fibrosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01961362|
Recruitment Status : Completed
First Posted : October 11, 2013
Results First Posted : February 25, 2020
Last Update Posted : February 25, 2020
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||19 participants|
|Official Title:||Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis|
|Study Start Date :||October 2013|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||December 2016|
Pulmonary fibrosis patients
Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
- Change in University of California San Diego Shortness of Breath Questionnaire From Immediately Prior to One Month After Starting Daily-use Supplemental Oxygen [ Time Frame: UCSD SOB score at one month after being prescribed supplemental O2 ]The University of California San Diego Shortness of Breath Questionnaire (or UCSD SOB) is a tool that measures shortness of breath using 24 items, each with response options ranging from 0 to 5, corresponding to "None at all" and "Maximally or unable to do because of breathlessness." Thus, scores for the UCSD SOB range from 0 to 120, with higher scores indicating greater shortness of breath.
- Change in Physical Component Summary (PCS) Score From the Medical Outcomes Study Short-Form, 36-item Questionnaire (SF-36). [ Time Frame: One month after daily-use supplemental oxygen implementation ]The PCS of the SF-36 assesses a domain of quality of life. Its scores range from 0-100, with higher scores indicating better quality of life on this domain.
- Fatigue Severity Scale [ Time Frame: One month after daily-use supplemental oxygen implementation ]The Fatigue Severity Scale is a 9-item questionnaire, scored from 9-63, with higher scores indicating more severe fatigue.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01961362
|United States, Colorado|
|National Jewish Health Interstitial Lung Disease Program|
|Denver, Colorado, United States, 80206|
|Principal Investigator:||Jeff Swigris, DO, MS||National Jewish Health|